AMAG Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 90   

Articles published

AMAG 44.51 +0.17 (0.38%)
price chart
Triferic: The Kill Shot For AMAG Pharmaceuticals' Feraheme (AMAG)
AMAG Pharmaceuticals (NASDAQ:AMAG) has issued puzzling guidance for Feraheme in 2015: Sales are projected to grow from ~$86 Million in 2014 to a range of approximately $86-102 MM in 2015 (note: the company now provides guidance on Feraheme ...
FBR Capital Markets Reaffirms Market Perform Rating for AMAG ...  sleekmoney
FBR Capital Markets Reiterates "Market Perform" Rating for AMAG ...  Ticker Report
AMAG Pharmaceuticals, Inc. Investors Encouraged to Contact Securities Law ...
28, 2015 /PRNewswire/ -- Securities lawyers at Dunnam & Dunnam are investigating allegations for AMAG Pharmaceuticals, Inc. shareholders AMAG, +0.38% Concerned AMAG investors who purchased between December 24, 2012 and January 8, 2015 are ...
AMAG Pharmaceuticals - The Short Story Gets Even Better (AMAG)
Unfortunately, those results suggest a far less profitable business than AMAG has portrayed. Here are the results of the successor company from September 16, 2013, to March 31, 2014: [Please see AMAG Pharmaceuticals' recent 8-K filing at www.sec.gov ...
Short Interest of AMAG Pharmaceuticals, Inc. Drops by 2.4%  Stafford Daily
AMAG Pharmaceuticals, Inc. to Present at the 33rd Annual JP Morgan ...
AMAG Pharmaceuticals, Inc. AMAG, +0.17% a specialty pharmaceutical company, announced today that William Heiden, AMAG's president and chief executive officer, will provide an update on the company followed by a breakout session at the 33rd Annual ...
Stock Insight : AMAG Pharmaceuticals Inc (NASDAQ:AMAG)
AMAG Pharmaceuticals Inc (NASDAQ:AMAG) (TREND ANALYSIS) is expected to report earnings per share of $0.38 for the current fiscal year, as per consensus of analysts.
AMAG Pharmaceuticals Earns "Hold" Rating from JPMorgan Chase & ...  sleekmoney
AMAG Pharmaceuticals Provides Business Update and 2015 Financial Guidance
11, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today provided a business update, including preliminary unaudited 2014 fourth quarter and annual financial results and its financial outlook for 2015.
AMAG Pharma reports preliminary Q4 results and 2015 guidance (AMAG)  Seeking Alpha
Amag Pharma 4Q, 2015 revenue forecasts top expectations  News & Observer
AMAG Pharmaceuticals (AMAG) in Focus: Stock Rises 5.8%
AMAG Pharmaceuticals (AMAG - Snapshot Report) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
AMAG Pharmaceuticals (AMAG) in Focus: Stock Rises 5.8% - Tale of the Tape  Nasdaq
AMAG Pharmaceuticals Now Covered by Analysts at FBR Capital Markets (AMAG)
Analysts at Jefferies Group raised their price target on shares of AMAG Pharmaceuticals from $40.00 to $55.00 and gave the company a �buy� rating in a research note on Friday, January 16th. Separately, analysts at JPMorgan Chase & Co. reiterated a ...
AMAG Pharmaceuticals Given "Market Perform" Rating at FBR Capital ...  Intercooler
Investment Analysts' New Coverage for January, 26th (AMAG, ARUN, BLND ...  Mideast Time
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces ...
NEW YORK, Jan. 12, 2015 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of AMAG Pharmaceuticals, Inc. ("AMAG" or the "Company") (NasdaqGS: AMAG ...
Brokerage Firm Price Target on AMAG Pharmaceuticals, Inc.
Equity Analysts at the Jefferies maintains the rating on AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). The brokerage firm has issued a Buy rating on the shares.